Sign in

You're signed outSign in or to get full access.

CARLISLE COMPANIES (CSL)

--

Earnings summaries and quarterly performance for CARLISLE COMPANIES.

Recent press releases and 8-K filings for CSL.

Carlisle Reports Q4 and Full Year 2025 Results and Reaffirms Vision 2030 Targets
CSL
Earnings
Guidance Update
Share Buyback
  • For the full year 2025, Carlisle delivered $5 billion in revenue, $19.40 adjusted EPS, 24.4% adjusted EBITDA margins, and 25% ROIC. The company generated $972 million in free cash flow, representing a 19.4% margin.
  • In the fourth quarter of 2025, revenue was approximately $1.1 billion, adjusted EPS was $3.90, and adjusted EBITDA margin was 22.1%. Organic revenue declined 3% due to soft new construction activity, partially offset by solid commercial reroofing demand.
  • Carlisle returned $1.3 billion to shareholders through share repurchases and $181 million through dividends in 2025. For 2026, the company expects low single-digit consolidated revenue growth and approximately 50 basis points of adjusted EBITDA margin expansion.
  • The company reaffirmed its Vision 2030 targets of $40 adjusted EPS and more than 25% ROIC, with goals of 30%+ EBITDA margins at CCM and 25%+ at CWT.
3 days ago
Carlisle Reports Q4 and Full-Year 2025 Results, Provides 2026 Outlook and Reaffirms Vision 2030 Targets
CSL
Earnings
Guidance Update
Share Buyback
  • Carlisle reported full-year 2025 revenue of $5 billion and adjusted EPS of $19.40, with adjusted EBITDA margins of 24.4% and ROIC of approximately 25%. For Q4 2025, revenue was $1.1 billion and adjusted EPS was $3.90.
  • The company generated $972 million in free cash flow (19.4% margin) in 2025 and returned nearly $1.5 billion to shareholders, including $1.3 billion in share repurchases and $181 million in dividends.
  • For 2026, Carlisle anticipates low single-digit revenue growth and approximately 50 basis points of adjusted EBITDA margin expansion, alongside plans to repurchase $1 billion of shares. The company also reaffirmed its Vision 2030 targets of $40 adjusted EPS and over 25% ROIC.
  • The company noted steady reroofing demand, which represents approximately 70% of its CCM business and is expected to grow low to mid-single digits in 2026, while the new commercial construction market remains soft with a projected gradual bottoming out mid-year.
3 days ago
Carlisle announces Q4 and Full Year 2025 results
CSL
Earnings
Guidance Update
Share Buyback
  • Carlisle reported $1.1 billion in revenue and $3.90 adjusted EPS for Q4 2025, contributing to $5.0 billion in full-year 2025 revenues and $19.40 adjusted EPS.
  • The company generated $1.1 billion in operating cash flow and $972 million in free cash flow for FY 2025, returning $1.5 billion to shareholders through dividends and share buybacks.
  • For full year 2026, Carlisle projects low single-digit revenue growth and 50 basis points of Adjusted EBITDA Margin expansion.
  • As of December 31, 2025, Carlisle maintained $2.1 billion in total liquidity and a Net Debt to EBITDA ratio of 1.4x.
3 days ago
Carlisle Reports Q4 and Full Year 2025 Results, Provides 2026 Outlook
CSL
Earnings
Guidance Update
Share Buyback
  • For the full year 2025, Carlisle delivered $5 billion in revenue and $19.40 in adjusted EPS, with adjusted EBITDA margins of 24.4% and ROIC of approximately 25%.
  • The company generated $972 million in free cash flow (19.4% margin) in 2025 and returned $1.3 billion to shareholders through share repurchases and $181 million through dividends.
  • In Q4 2025, Carlisle reported $1.1 billion in revenue and $3.90 in adjusted EPS, with organic revenue declining 3% due to soft new construction activity, partially offset by solid commercial reroofing demand.
  • Looking ahead to 2026, Carlisle expects low single-digit consolidated revenue growth and approximately 50 basis points of adjusted EBITDA margin expansion, with plans to repurchase $1 billion of shares. The company reaffirmed its Vision 2030 targets of $40 adjusted EPS and over 25% ROIC.
3 days ago
Carlisle Companies Reports Fourth Quarter and Full Year 2025 Results
CSL
Earnings
Guidance Update
Share Buyback
  • Carlisle Companies reported Q4 2025 revenue of $1.1 billion, a 0.4% year-over-year increase, with diluted EPS of $3.19 and adjusted EPS of $3.90.
  • For the full year 2025, the company generated $1.1 billion in operating cash flow and repurchased $1.3 billion of shares, including $300 million in Q4 2025.
  • The 2026 outlook anticipates low-single-digit revenue growth and approximately 50 basis points of adjusted EBITDA margin expansion, with plans to repurchase up to $1 billion of shares.
3 days ago
Carlisle Companies Reports Fourth Quarter and Full Year 2025 Results
CSL
Earnings
Guidance Update
Share Buyback
  • Carlisle Companies reported fourth quarter 2025 revenue of $1.1 billion, an increase of 0.4% year-over-year, with diluted EPS of $3.19 and adjusted EPS of $3.90.
  • For the full year 2025, the company generated $1.1 billion in operating cash flow and repurchased $1.3 billion of shares, including $300 million in Q4.
  • The 2026 outlook includes low-single-digit revenue growth and approximately 50 basis points of adjusted EBITDA margin expansion.
  • Carlisle plans to repurchase up to $1 billion of shares in 2026 and maintains a long-term objective of delivering $40 of adjusted EPS.
3 days ago
CSL announces five-year results for HEMGENIX gene therapy
CSL
  • CSL announced five-year (60-month) results from the pivotal Phase 3 HOPE-B study for HEMGENIX, confirming the long-term durability and safety of the one-time gene therapy for adults with hemophilia B.
  • The study demonstrated that 94% of patients (51 of 54) remained free from continuous prophylaxis treatment through five years, with mean factor IX activity levels sustained at 36.1% at year five.
  • HEMGENIX significantly reduced bleeding rates, with the mean adjusted annualized bleeding rate (ABR) for all bleeds decreasing by approximately 90% (from 4.16 to 0.40) from lead-in to year five.
  • The therapy maintained a favorable safety profile, with no serious adverse events related to treatment, and is the only commercially available gene therapy for adults with hemophilia B.
Dec 7, 2025, 5:01 PM
Carlisle Reports Q3 2025 Results and Updates Full-Year Guidance
CSL
Earnings
Guidance Update
Share Buyback
  • Carlisle (CSL) reported Q3 2025 revenue of $1.3 billion, an increase of 1% year-over-year, and adjusted EPS of $5.61.
  • The company revised its full-year 2025 guidance to anticipate flat revenue year-over-year and an adjusted EBITDA margin decline of approximately 250 basis points.
  • Performance was driven by the strength of the underlying CCM business, particularly strong reroofing demand, which was partially offset by ongoing challenges in residential and non-residential new construction markets.
  • Carlisle maintained its commitment to capital deployment, repurchasing 800,000 shares for $300 million in Q3, raising its dividend by 10%, and increasing its full-year share buyback target to $1.3 billion.
  • The company also issued $1 billion of debt in Q3, maintaining a net debt to EBITDA ratio of 1.4 times as of September 30, 2025.
Oct 29, 2025, 9:00 PM
Carlisle Companies Announces Q3 2025 Results and Revised Full-Year Outlook
CSL
Earnings
Guidance Update
Share Buyback
Demand Weakening
  • CSL reported Q3 2025 revenue of $1,347 million, a 1% year-over-year increase, with Adjusted EPS of $5.61 and an Adjusted EBITDA Margin of 25.9%.
  • The company returned $347 million to shareholders in Q3 2025 through dividends and share repurchases, and increased its share buyback target for the year to $1.3 billion.
  • CSL revised its full-year 2025 outlook to project flat revenue year-over-year and an Adjusted EBITDA margin compression of 250 basis points from 2024.
  • Performance was influenced by M&A contributions and strong commercial re-roofing, which helped to offset lower volumes from soft new construction and residential R&R markets.
Oct 29, 2025, 9:00 PM
Carlisle Companies Incorporated Announces Q3 2025 Results and Updates Full-Year Guidance
CSL
Earnings
Guidance Update
Share Buyback
  • Carlisle Companies Incorporated reported Q3 2025 revenue of $1.3 billion, a 1% year-over-year increase, though organic revenue declined 2%.
  • Adjusted EPS was $5.61, down 3% from the prior year, with an adjusted EBITDA margin of 25.9%, a 170 basis point decrease.
  • The company revised its full-year 2025 guidance, now expecting consolidated revenue to be flat year-over-year and adjusted EBITDA margin to decline approximately 250 basis points.
  • Carlisle increased its full-year 2025 share buyback target to $1.3 billion and announced a 10% dividend increase, its 49th consecutive annual increase.
Oct 29, 2025, 9:00 PM